To facilitate the identification of the right patient population for each oncology compound, Champions TumorGrafts™ are highly characterized, with the following data available to guide model selection and analysis:

• Gene expression profile
• Oncogene mutations
• Growth and response to standard of care agents
• Clinical annotations from patients

Our platform enables identification of the most promising development path for a compound in terms of:

• Tumor types
• Drug combinations
• Biomarkers
• Patient subpopulations

And the platform eliminates wasted development time and expense on not-likely-to-respond indications and patient populations.